Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VT-1161 in toenail onychomycosis
NCT02267356Phase 2Completed
- Sponsor
- Viamet Pharmaceuticals
- Start
- Feb 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oteseconazole in onychomycosis (5 arms), sponsored by Viamet Pharmaceuticals. Primary endpoint: Proportion of Subjects with Complete Cure (Clinical AND Mycological Cure) at 48 weeks. Started Feb 2015; status: completed.
02
Drugs
oteseconazole
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT02267356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267356.